EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond Fumigatus : a molecular portrait of clinical Aspergillus diversity, pathogenicity, and antifungal resistance

Chioma I Aneke, Sherin S Shahegh, Alexandra F Freeman iD, Christa Zerbe iD, Kyung J Kwon-Chung iD, Steven Holland, Kevin Fennelly, Michail S Lionakis iD, Amir Seyedmousavi iD

Antimicrobial Agents and Chemotherapy · 04.02.2026 · 70 (2)

DOI: 10.1128/aac.01184-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.02.2026. Verfasst von Chioma I Aneke und 8 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Drug Resistance, Fungal, Aspergillus, Aspergillosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aspergillus infection poses a major clinical challenge, particularly in immunocompromised individuals, with invasive diseases associated with high mortality. While Aspergillus fumigatus remains the predominant species causing human infections, recent studies highlight the growing clinical significance of lesser-known and cryptic Aspergillus species, which often exhibit reduced susceptibility to standard antifungal therapies. In this study, we analyzed 196 clinical Aspergillus isolates from 107 patients treated at the NIH Clinical Center between 2019 and 2022. A total of 38 Aspergillus species across 11 taxonomic sections were identified, with non- fumigatus and cryptic species accounting for 77.1% of all isolates. The most frequently recovered species were A. fumigatus sensu stricto (22.9%), A. sydowii (8.7%), A. calidoustus (7.1%), A. nidulans (6.6%), A. tanneri (6.1%), and A. terreus (5.6%). Species-level identification was achieved in 43% of isolates using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). In contrast, PCR sequencing confirmed species identity in over 88% of isolates by targeting the internal transcribed spacer (ITS) region of rDNA, 81% using the β-tubulin gene, and 68% using the calmodulin gene. The most common underlying clinical conditions among patients were bronchiectasis (35%), chronic granulomatous disease (22%), and pulmonary non-tuberculous mycobacterial infection (17%). Out of 107 patients, eight died (8/107, 7.5%); six of these deaths occurred in patients with chronic granulomatous disease (CGD) and two in patients with RAG1 deficiency. Antifungal susceptibility testing showed that olorofim had the lowest minimal inhibitory concentrations across species. In contrast, the activity of triazoles and amphotericin B was variable, particularly against A. tanneri , A. calidoustus , and A. sydowii . This study presents one of the largest species-level data sets of Aspergillus isolates to date, underscoring the diversity, pathogenic potential, and resistance profiles of non- fumigatus species. Accurate species identification plays an important role in guiding appropriate antifungal therapy and improving clinical outcomes, although further studies are needed to elucidate its direct impact on treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsDrug Resistance, FungalAspergillusAspergillosisAspergillus fumigatusHumansMicrobial Sensitivity Tests

Stichwörter der Autor:innen

MALDI-TOF MSantifungal susceptibilityaspergillosisclinical Aspergillus diversitycryptic Aspergillus speciesnon-fumigatus Aspergillus speciespathogenicityspecies-level identification

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Pulmonary Clinical Medicine Section, Cardiovascular Pulmonary Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Alexandra F Freeman, Christa Zerbe, Kyung J Kwon-Chung, Michail S Lionakis, Amir Seyedmousavi

Förderung

  • Intramural NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Aneke, C. I., Shahegh, S. S., Freeman, A. F., Zerbe, C., Kwon-Chung, K. J., Holland, S., Fennelly, K., Lionakis, M. S., & Seyedmousavi, A. (2026). Beyond Fumigatus : a molecular portrait of clinical Aspergillus diversity, pathogenicity, and antifungal resistance. Antimicrobial Agents and Chemotherapy, 70(2). https://doi.org/10.1128/aac.01184-25

Vancouver

Aneke CI, Shahegh SS, Freeman AF, Zerbe C, Kwon-Chung KJ, Holland S, et al. Beyond Fumigatus : a molecular portrait of clinical Aspergillus diversity, pathogenicity, and antifungal resistance. Antimicrobial Agents and Chemotherapy. 2026;70(2). doi:10.1128/aac.01184-25

BibTeX
@article{Aneke2026,
  author = {Aneke, Chioma I and Shahegh, Sherin S and Freeman, Alexandra F and Zerbe, Christa and Kwon-Chung, Kyung J and Holland, Steven and Fennelly, Kevin and Lionakis, Michail S and Seyedmousavi, Amir},
  title = {Beyond Fumigatus : a molecular portrait of clinical Aspergillus diversity, pathogenicity, and antifungal resistance},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {2},
  doi = {10.1128/aac.01184-25}
}
Kostenlos starten →